Patents by Inventor Michael Allen Collingwood
Michael Allen Collingwood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12351799Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRSPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.Type: GrantFiled: December 5, 2024Date of Patent: July 8, 2025Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Christopher Anthony Vakulskas, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
-
Publication number: 20250197851Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRSPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.Type: ApplicationFiled: November 26, 2024Publication date: June 19, 2025Applicant: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Christopher Anthony Vakulskas, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
-
Publication number: 20250179457Abstract: This invention pertains to mutant Lachnospiraceae bacterium ND2006 (Lb) Cas12a nucleic acids and proteins for use in CRISPR/Cas12a endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant LbCas12a protein, wherein the isolated mutant LbCas12a protein is active in a CRISPR/Cas12a endonuclease system. The invention also includes isolated nucleic acids encoding mutant LbCas12a proteins, ribonucleoprotein complexes and CRISPR/Cas12a endonuclease systems having mutant LbCas12a proteins.Type: ApplicationFiled: February 24, 2025Publication date: June 5, 2025Inventors: Sarah Franz BEAUDOIN, Michael Allen COLLINGWOOD, Christopher Anthony VAKULSKAS
-
Publication number: 20250122491Abstract: This invention pertains to optimized protein fusion linkers for creating multi-functional chimeric proteins and methods of using the same. Additionally, the invention pertains to chimeric proteins for use in guided endonuclease systems and methods of using the same.Type: ApplicationFiled: October 7, 2024Publication date: April 17, 2025Applicant: Integrated DNA Technologies, Inc.Inventors: Michael Allen Collingwood, Steve Ehren Glenn, Christopher Anthony Vakulskas
-
Publication number: 20250109395Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRSPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.Type: ApplicationFiled: December 5, 2024Publication date: April 3, 2025Applicant: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Christopher Anthony Vakulskas, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
-
Patent number: 12264342Abstract: This invention pertains to mutant Lachnospiraceae bacterium ND2006 (Lb) Cas12a nucleic acids and proteins for use in CRISPR/Cas12a endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant LbCas12a protein, wherein the isolated mutant LbCas12a protein is active in a CRISPR/Cas12a endonuclease system. The invention also includes isolated nucleic acids encoding mutant LbCas12a proteins, ribonucleoprotein complexes and CRISPR/Cas12a endonuclease systems having mutant LbCas12a proteins.Type: GrantFiled: February 21, 2020Date of Patent: April 1, 2025Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Sarah Franz Beaudoin, Michael Allen Collingwood, Christopher Anthony Vakulskas
-
Patent number: 12168765Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRISPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.Type: GrantFiled: July 21, 2022Date of Patent: December 17, 2024Assignee: Integrated DNA Technologies, Inc.Inventors: Christopher Anthony Vakulskas, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
-
Patent number: 12152258Abstract: This invention pertains to optimized protein fusion linkers for creating multi-functional chimeric proteins and methods of using the same. Additionally, the invention pertains to chimeric proteins for use in guided endonuclease systems.Type: GrantFiled: April 20, 2021Date of Patent: November 26, 2024Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Michael Allen Collingwood, Steve Ehren Glenn, Christopher Anthony Vakulskas
-
Publication number: 20240318171Abstract: This invention pertains to modified compositions for use in CRISPR systems, and their methods of use. In particular, length-modified and chemically-modified forms of crRNA are described for use as a reconstituted guide RNA for interaction with Cas9 of CRISPR systems. The resultant length-modified and chemically-modified forms of crRNA are economical to produce and can be tailored to have unique properties relevant to their biochemical and biological activity in the context of the CRIPSR Cas9 endonuclease system.Type: ApplicationFiled: January 4, 2024Publication date: September 26, 2024Applicant: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Michael Allen Collingwood, Ashley Mae Jacobi, Garrett Richard Rettig, Mollie Sue Schubert, Mark Aaron Behlke, Christopher Anthony Vakulskas, Rolf Turk
-
Publication number: 20240309402Abstract: This invention pertains to isolated mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays a lower ratio of reduced off-target editing activity to on-target editing activity for at least one target site relative to the corresponding ratio of reduced off-site editing activity to on-target editing activity of a wild-type CRISPR/Cas endonuclease system having a WT-Cas9 protein of SEQ ID NO:5.Type: ApplicationFiled: January 20, 2024Publication date: September 19, 2024Applicant: Integrated DNA Technologies, Inc.Inventors: Christopher Anthony Vakulskas, Nicole Mary Bode, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
-
Publication number: 20240199691Abstract: Described herein are methods for the expression and purification of Cas13a and methods for detecting target RNA using Cas13a.Type: ApplicationFiled: January 18, 2024Publication date: June 20, 2024Inventors: Sarah Franz BEAUDOIN, Michael Allen COLLINGWOOD, Christopher Anthony VAKULSKAS, Mark Aaron BEHLKE
-
Patent number: 12012433Abstract: Described herein are methods for the expression and purification of Cas13a and methods for detecting target RNA using Cas13a.Type: GrantFiled: February 25, 2021Date of Patent: June 18, 2024Assignee: INTEGRATED DNA TECHNOLOGIES INC.Inventors: Sarah Franz Beaudoin, Michael Allen Collingwood, Christopher Anthony Vakulskas, Mark Aaron Behlke
-
Patent number: 11932667Abstract: Described herein are methods for the expression and purification of Cas13a and methods for detecting target RNA using Cas13a.Type: GrantFiled: February 25, 2021Date of Patent: March 19, 2024Assignee: INTEGRATED DNNA TECHNOLOGIES INC.Inventors: Sarah Franz Beaudoin, Michael Allen Collingwood, Christopher Anthony Vakulskas, Mark Aaron Behlke
-
Patent number: 11913014Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRSPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.Type: GrantFiled: February 7, 2022Date of Patent: February 27, 2024Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Christopher Anthony Vakulskas, Nicole Mary Bode, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
-
Publication number: 20240059747Abstract: The present invention pertains to a tag-free CM1 polypeptide and methods for improving homology directed repair (HDR) in a recipient cell using the same. Preferred donor template delivery vehicles include Adeno virus-associated vectors for delivering donor templates, and a preferred tag-free CM1 polypeptide called CM1tf. Isolated nucleic acids encoding tag-free CM1 polypeptides are also provided.Type: ApplicationFiled: August 15, 2023Publication date: February 22, 2024Inventors: Steve Ehren Glenn, Michael Allen Collingwood, Christopher Anthony Vakulskas
-
Publication number: 20230133277Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRSPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.Type: ApplicationFiled: July 21, 2022Publication date: May 4, 2023Inventors: Christopher Anthony Vakulskas, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
-
Publication number: 20230138679Abstract: The present disclosure concerns polynucleotides and amino acids of Acidaminococcus sp. Cas12a (Cpf1) and methods for their use for genome editing in eukaryotic cells.Type: ApplicationFiled: July 26, 2022Publication date: May 4, 2023Inventors: Liyang Zhang, Christopher Anthony Vakulskas, Nicole Mary Bode, Michael Allen Collingwood, Kristin Renee Beltz, Mark Aaron Behlke
-
Publication number: 20230049003Abstract: This invention pertains to optimized protein fusion linkers for creating multi-functional chimeric proteins and methods of using the same. Additionally, the invention pertains to chimeric proteins for use in guided endonuclease systems.Type: ApplicationFiled: April 20, 2021Publication date: February 16, 2023Inventors: Michael Allen Collingwood, Steve Ehren Glenn, Christopher Anthony Vakulskas
-
Publication number: 20230040148Abstract: This invention pertains to mutant Lachnospiraceae bacterium ND2006 (Lb) Cas12a nucleic acids and proteins for use in CRISPR/Cas12a endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant LbCas12a protein, wherein the isolated mutant LbCas12a protein is active in a CRISPR/Cas12a endonuclease system. The invention also includes isolated nucleic acids encoding mutant LbCas12a proteins, ribonucleoprotein complexes and CRISPR/Cas12a endonuclease systems having mutant LbCas12a proteins.Type: ApplicationFiled: February 21, 2020Publication date: February 9, 2023Inventors: Sarah Franz BEAUDOIN, Michael Allen COLLINGWOOD, Christopher Anthony VAKULSKAS
-
Publication number: 20220340931Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRSPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.Type: ApplicationFiled: February 7, 2022Publication date: October 27, 2022Inventors: Christopher Anthony Vakulskas, Nicole Mary Bode, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke